MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >

Welcome to the MDS Patient Message Board Post New Thread

Welcome to the MDS Patient Message Board. We hope that you will find this to be a very valuable resource in your journey. We have recently revised the format of our forum to be much more user friendly and pleasing on the eyes. Let us know if you have any problems, or if you have additional suggestions on how we might further improve our site.

Inqovi

Home forums Patient Message Board Inqovi

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #52323
    Aureta
    Participant

    I saw where Inqovi a pill form drug was just FDA approved for MDS. Has anyone heard of this drug?

    #52324
    Amy Clark
    Participant

    Yes, it is the HMA (hypomethylating agent) Dacogen (decitabine) in a pill form with an inhibitor cedazuridine. The cedazurine keeps the Dacogen from being broken down too early. This was previously known as ASTX727 in the clinical trails. My husband has been taking it in the clinical trial and started his 17th cycle today. We didn’t see much improvement until the 7th cycle, but since that time he has not needed another blood transfusion. Yeah! However, he still has blasts and the mutations and dysplasia in his blood and bone marrow, so they don’t consider him in remission. He takes all of the pills at home and goes into the clinic for labs routinely. The first cycle sent him to the hospital with febrile neutropenia.

    You have to be really patient with HMAs (Dacogen and Vidaza) as they often take awhile to work.

    Here is a link and a quote: “The ASCERTAIN phase 3 study data confirms the hypothesis that by inhibiting cytidine deaminase in the gut, systemic therapeutic concentrations of decitabine can be delivered orally to achieve decitabine systemic exposure equivalent to IV dosing,” said Dr Garcia-Manero. “The data support that ASTX727 could become an oral hypomethylating agent alternative to IV decitabine.”

    Astex Pharmaceuticals presents topline data from the ASCERTAIN phase 3 study of its novel, oral hypomethylating agent cedazuridine and decitabine (ASTX727) in MDS and CMML at the American Society of Hematology Meeting in Orlando, FL.

    Hope that helps! Amy

Viewing 2 posts - 1 through 2 (of 2 total)

Register for an account, or login to post to our message boards. Click here.

  • You must be logged in to reply to this topic.

Login

Login

Search Forums

Review answers to commonly asked questions or get answers to your questions from an MDS expert